Evaluation of clinicopathologic characteristics and the BRAF V600E mutation in Erdheim-Chester disease among Chinese adults

详细信息    查看全文

• 作者：Xin-xin Cao ; Jian Sun ; Jian Li ; Ding-rong Zhong ; Na Niu…
• 关键词：Erdheim ; Chester disease ; BRAF V600E mutation ; Histiocytosis
• 刊名：Annals of Hematology
• 出版年：2016
• 出版时间：April 2016
• 年：2016
• 卷：95
• 期：5
• 页码：745-750
• 全文大小：243 KB
• 参考文献：1.Writing Group of the Histiocyte Society (1987) Histiocytosis syndromes in children. Lancet 329:208–209
  2.Emile JF, Wechsler J, Brousse N et al (1995) Langerhans’ cell histiocytosis. Definitive diagnosis with the use of monoclonal antibody O10 on routinely paraffin-embedded samples. Am J Surg Pathol 19:636–641CrossRef PubMed
  3.International Agency for Research in Cancer (2006) World Health Organization Classification of tumours: pathology and genetics of tumours of the skin. Lyon
  4.International Agency for Research in Cancer (2008) WHO Classification of tumours of haematopoietic and lymphoid tissues. Lyon
  5.Haroche J, Charlotte F, Arnaud L et al (2012) High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses. Blood 120:2700–2703CrossRef PubMed
  6.Blombery P, Wong SQ, Lade S, Prince HM (2012) Erdheim-Chester disease harboring the BRAF V600E mutation. J Clin Oncol 30:e331–e332CrossRef PubMed
  7.Bubolz AM, Weissinger SE, Stenzinger A et al (2014) Potential clinical implications of BRAF mutations in histiocytic proliferations. Oncotarget 5:4060–4070CrossRef PubMed PubMedCentral
  8.Diamond EL, Dagna L, Hyman DM et al (2014) Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease. Blood 124:483–492CrossRef PubMed PubMedCentral
  9.Haroche J, Arnaud L, Cohen-Aubart F et al (2013) Erdheim-Chester disease. Rheum Dis Clin N Am 39:299–311CrossRef
  10.Cangi MG, Biavasco R, Cavalli G et al (2015) BRAFV600E-mutation is invariably present and associated to oncogene-induced senescence in Erdheim-Chester disease. Ann Rheum Dis 74:1596–1602CrossRef PubMed
  11.Hervier B, Haroche J, Arnaud L et al (2014) Association of both Langerhans cell histiocytosis and Erdheim-Chester disease linked to the BRAFV600E mutation. Blood 124:1119–1126CrossRef PubMed
  12.Stoppacciaro A, Ferrarini M, Salmaggi C et al (2006) Immunohistochemical evidence of a cytokine and chemokine network in three patients with Erdheim-Chester disease: implications for pathogenesis. Arthritis Rheum 54:4018–4022CrossRef PubMed
  13.Arnaud L, Gorochov G, Charlotte F et al (2011) Systemic perturbation of cytokine and chemokine networks in Erdheim-Chester disease: a single-center series of 37 patients. Blood 117:2783–2790CrossRef PubMed
  14.Aouba A, Georgin-Lavialle S, Pagnoux C et al (2010) Rationale and efficacy of interleukin-1 targeting in Erdheim-Chester disease. Blood 116:4070–4076CrossRef PubMed
  15.Braiteh F, Boxrud C, Esmaeli B, Kurzrock R (2005) Successful treatment of Erdheim-Chester disease, a non-Langerhans-cell histiocytosis, with interferon-α. Blood 106:2992–2994CrossRef PubMed
  16.Cavalli G et al (2013) The multifaceted clinical presentations and manifestations of Erdheim-Chester disease: comprehensive review of the literature and of 10 new cases. Ann Rheum Dis 72:1691–1695CrossRef PubMed
  17.Haroche J, Cohen-Aubart F, Emile JF et al (2015) Reproducible and sustained efficacy of targeted therapy with vemurafenib in patients with BRAFV600E-mutated Erdheim-Chester disease. J Clin Oncol 33:411–418CrossRef PubMed
  
• 作者单位：Xin-xin Cao (1)
  Jian Sun (2)
  Jian Li (1)
  Ding-rong Zhong (2)
  Na Niu (3)
  Ming-hui Duan (1)
  Zhi-yong Liang (2)
  Dao-bin Zhou (1)
  
  1. Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
  2. Department of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
  3. Department of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
  
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Hematology
  Oncology
  
• 出版者：Springer Berlin / Heidelberg
• ISSN：1432-0584

文摘

Erdheim-Chester disease (ECD) is a rare form of histiocytosis with a broad, non-specific clinical spectrum. Here, we retrospectively evaluated the clinical and pathologic characteristics, presence of the BRAF V600E mutation, treatment options, and outcomes of Chinese patients diagnosed with ECD at our center. Patients diagnosed with ECD between January 2010 and April 2015 at Peking Union Medical College Hospital were included for study. We evaluated baseline characteristics, reviewed histological material, and tested for the presence of the BRAF V600E mutation using immunohistochemistry and polymerase chain reaction (PCR). Sixteen patients were diagnosed with ECD. Median disease duration (from the first symptom to diagnosis) was 22.5 months (range, 3–100 months). The main sites of involvement included bone (93.8 %), cardiovascular region (43.8 %), skin (31.3 %), central nervous system (25 %), and “hairy kidney” (25 %). The BRAF V600E mutation was detected in 68.8 % patients using PCR and 50 % patients with immunohistochemistry. Three patients could not be diagnosed using histological analysis owing to similarities with Rosai-Dorfman disease, and diagnosis in these cases was confirmed based on the BRAF V600E mutation status. Ten patients (62.5 %) received IFN-α as first-line treatment. Thirteen patients (81.3 %) were still alive at median follow-up of 14.5 months. ECD remains a largely overlooked disease, and increased recognition by clinicians and pathologists is necessary for effective diagnosis and treatment. The presence of the BRAF V600E mutation may facilitate discrimination of ECD from other non-Langerhans cell histiocytoses.